Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules-Reference-Cited by-同舟云学术

Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules

Published:2020-09 Issue: Volume:44 Page:102311
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Fuentes-Rumí Luna^ORCID,Hernández-Clares Rocío^ORCID,Carreón-Guarnizo Ester,Valero-López Gabriel,Iniesta-Martinez Francisca^ORCID,Cabrera-Maqueda Jose Maria,León-Hernández Adelaida,Zamarro-Parra Joaquín,Morales-Ortiz Ana,Meca-Lallana José E

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference25 articles.

1. Disease modifying therapies for relapsing multiple sclerosis;Wingerchuk;BMJ,2016

2. Natalizumab treatment of multiple sclerosis: new insights;Delbue;Immunotherapy,2017

3. Natalizumab in multiple sclerosis: long-term management;Clerico;Int. J. Mol. Sci.,2017

4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies;Wingerchuk;Mayo Clin. Proc.,2014

5. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients;Vellinga;Neurology,2008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early high efficacy mulitple sclerosis treatment: therapeutic success despite safety barriers;Neurologie pro praxi;2023-12-07

2. Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis;Journal of Neurology, Neurosurgery & Psychiatry;2023-02-20

3. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study;Frontiers in Immunology;2023-02-01

4. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis;CNS Drugs;2022-11-09

5. Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry;Neurology and Therapy;2022-01-12